Clinical trial NCT01513174: Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Official title: Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Non Small Cell Lung Cancer
Keywords: GOAL
Lung
Non small cell lung cancer
EGFR mutations
Lead sponsor: Spanish Lung Cancer Group
Sponsor class: OTHER
First posted: 2012-01-20
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study of gefitinib plus olaparib gefitinib in combination with olaparib (AZD2281) versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced non-small-cell lung cancer.

Detailed description: GOAL is a multicenter, randomized phase IB/II study performed in two countries, Spain and Mexico. Eligible patients were 18 years or older, treatment-naïve, pathologically confirmed stage IV NSCLC, with centrally confirmed EGFR mutations and measurable disease. Patients were randomly allocated (1:1) to receive gefitinib 250 mg daily or gefitinib 250 mg daily plus olaparib 200 mg three times daily in 28-day cycles. The primary endpoint was PFS. Secondary endpoints included overall survival (OS), response rate, safety and tolerability.

Eligibility criteria: Inclusion Criteria:

1. Patients age 18 years or more.
2. Histologically confirmed diagnosis of non-small-cell lung carcinoma.
3. Stage IV disease, following the Seventh Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (27).
4. Tumor tissue available (according to the criterion of the specimen-processing laboratory) for EGFR mutation assessment: to be included in the study patients should present at least one EGFR mutation (exon 19 deletion or L858R with or without T790M).
5. Evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.
6. ECOG score ≤ 2.
7. Life expectancy of ≥ 3 months.
8. For the Phase II part of the study, patients should not have received previous treatment with chemotherapy or other agents for advanced disease: chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neoadjuvant treatment, as long as a minimum of 6 months has passed since the end of the adjuvant and/or neo-adjuvant chemotherapy. This criterion is not mandatory to patients to be included in the Phase I part of the study (these patients are allowed to have received a prior line of treatment for advanced disease).
9. Patients with the following hematologic values:

   * Absolute Neutrophil Count (ANC) ≥1.5 x 109/L
   * Hemoglobin (Hb) ≥ 10 g/dl
   * Platelets ≥ 100 x 109/L
10. Patients with the following biochemical values:

    * Bilirubin ≤ 1.5 mg/dL
    * Aspartate aminotransferase (AST) and Alanine transaminase (ALT) \< 1.5 upper limit of normality
    * Creatinine clearance ≥ 60 ml/min.
11. Patients of childbearing age of either sex must use effective contraceptive methods(barrier methods plus other birth control methods) before entering the study and while participating in the study.
12. Patients should sign an informed consent form before inclusion in the study that specifies that the clinical trial treatment entails consent for the analysis of biological samples of tumor and blood.
13. Patients must be available for clinical follow-up.

Exclusion Criteria:

1. Patients diagnosed of another neoplasm, with the exception of cervical carcinoma insitu, treated squamous cell carcinoma or superficial bladder tumor (Ta and TIS), or other malignant tumors that have received curative treatment within the last 5 years before inclusion in the study.
2. Simultaneous participation in any other study involving an investigational medicinal product, or having participated in a study less than 28 days prior to the start of study treatment.
3. Patients with HIV infection, HCV infection, coronary disease or uncontrolled arrhythmia, uncontrolled cerebrovascular disease and other clinical conditions that, in the judgment of the investigator, contraindicate the patient's participation in the study.
4. Past medical history of interstitial lung disease (ILD), drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.
5. Pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline.
6. Uncontrolled seizures.
7. Patients considered requiring radiotherapy to the lung at the time of study entry or in the near future.
8. Known or suspected brain metastases or spinal cord compression, unless treated with surgery and/or radiation and stable without steroid treatment for at least 4 weeks prior to the first dose of study medication.
9. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
10. Patients who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test performed within 7 days before the onset of treatment(Appendix 8).
11. Patients receiving the following classes of inhibitors of CYP3A4 (see Appendix 5 for guidelines and wash out periods):

    * Azole antifungals
    * Macrolide antibiotics
    * Protease inhibitors
12. Concomitant use of known CYP3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
13. Major surgery within 2 weeks of starting study treatment; patients must have recovered from any effects of any major surgery.
14. Significant weight loss (= 10% of body weight) in the 6 weeks before inclusion in the study.
15. Any condition that is unstable or could endanger the patient's safety and/or the patient's compliance with the study.
16. Substance abuse or clinical, psychological or social conditions that can undermine the validity of the informed consent or protocol compliance.
17. Patients who present any contraindication or suspected allergy to the products under investigation in the study. Tablets of gefitinib contain lactose: patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose and galactose malabsorption, will not be included in this trial.
18. Contraindication for steroid use.
19. Impossibility to comply with treatment due to cultural or geographic circumstances.

Primary outcomes:
measure: Progression-free Survival (PFS)
timeFrame: From the date of randomization until end of follow up, up to 30 months.
Secondary outcomes:
measure: Overall Survival
timeFrame: From the date of randomization until end of follow up, up to 30 months
measure: Best Global Response During Treatment Period
timeFrame: From the date of randomization until end of follow up, up to 30 months
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: H. Germans Trias i Pujol
state: Barcelona
city: Hospitalet de Llobregat
country: Spain
facility: ICO Hospitalet
state: Barcelona
city: Alicante
country: Spain
facility: H. Gen. Universitario de Alicante
city: Barcelona
country: Spain
facility: H. Vall d'Hebrón
city: La Coruña
country: Spain
facility: H. Teresa Herrera
Study officials:
affiliation: Hospital Teresa Herrera
name: Maria Rosario García Campelo, MD
role: STUDY_CHAIR
References:
citation: Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Domine M, Reguart N, Guirado M, Sala MA, Vazquez-Estevez S, Caro RB, Drozdowskyj A, Verdu A, Karachaliou N, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group (SLCG). Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. Epub 2020 Oct 3.